Is the Pen Mightier Than the Stent?  by King, Spencer B.
EI
A
w
i
i
i
c
m
n
s
m
w
t
o
e
d
m
w
t
m
p
a
n
d
s
v
h
m
c
s
r
p
r
t
h
m
l
M
a
s
o
e
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 9 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 0 8 . 0 0 1
Spencer B. King III,
MD
Editor-in-Chief,
JACC: Cardiovascular
Interventions
We are the champi-
ons of acute coronary
syndromes, especially
the treatment of
ST-segment eleva-
tion myocardial
infarction.
Stable ischemic heart
disease is under in-
tensive review for
the most appropriate
therapies.
We, the interven-
tional cardiologists,
have spent our ca-
reers studying and
observing the
ravages of
atherothrombosis.
Who will be the
leaders in applying
this knowledge for
the most effective
and most cost-effec-
tive approaches?DITOR’S PAGE
s the Pen Mightier Than the Stent?
s I become increasingly depressed about the prospects of meaningful health care reform, I
onder in the early morning sleeplessness what we interventional cardiologists can do. The
nertia created by the self-interested components of healthcare delivery may result in squander-
ng an opportunity to fix a severely flawed system. It seems the insurance and pharmaceutical
ndustries have been given a by in the process, while the physicians and hospitals remain
learly in the crosshairs of the cost-savings initiative. I can claim no expertise on the business of
edical practice, which struggles to remain a profession but is now becoming no less a busi-
ess than the payers (nonpayers) or the sacred cows (non-negotiable drug prices). Whether we
ee a bill passed or not, the draconian cuts in reimbursement for imaging and interventions are
oving forward. How do we align the business of interventional practice with the profession
e love?
First, what do we do well? We are the champions of acute coronary syndromes, especially
he treatment of ST-segment elevation myocardial infarction. There is little discussion about
ur ability to interdict emergency coronary situations and save lives. We will continue to be
ffective in defending these endeavors. In addition, fantastic tools for treating structural heart
isease with less invasive and potentially less expensive therapies are being employed. Treat-
ent of peripheral obstructive disease causing disability is an area where we excel. Where are
e vulnerable? Stable ischemic heart disease is under intensive review for the most appropriate
herapies. “Stable” sounds benign but we know that all patients dropping dead from acute
yocardial infarction had stable ischemic heart disease at some point before the event. How to
revent the disaster from an interventional perspective leads to thoughts of imaging advances
nd pre-emptive interventional strikes with invasive local therapy. The problem is that we have
ot yet been able to demonstrate our ability to reliably predict either the site or the time of the
isaster. When there is ischemia we can improve symptoms, cardiac function, and in some
ituations, survival. As the FAME (Fractional Flow Reserve Versus Angiography for Multi-
essel Evaluation) trial showed, when the lesions are angiographically significant but not
emodynamically obstructive, an intervention is not effective. Nonetheless these patients will in
any cases develop cardiac disasters. How do we prevent those? The evidence points more
learly to the “Pen” than the “Promus.” Prescribed and complied with medical therapy has
trong evidence for prevention of cardiac events.
We, the interventional cardiologists, have spent our careers studying and observing the
avages of atherothrombosis. We know about effective therapies, understanding that many
atients benefit from blood pressure control, antiplatelet therapy, and low-density lipoprotein
eduction. We are increasingly convinced of the pleathrophic effects of statins. We also know
hat many metabolic defects may make the patient vulnerable to cardiac events. The raising of
igh-density lipoprotein in metabolic syndrome patients and control of other lipid abnor-
alities is gaining credibility. Glitazones in diabetic patients may stabilize atherosclerotic
esions, as may angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers.
ost interesting is the growing knowledge about genetic variations among patients with
therothrombosis including vulnerability to acute events and susceptibility to benefit from
tatin and thienopyridine therapy. In the near future the effectiveness of a personalized attack
n preventing progression of atherothrombosis and cardiac events will become more evident.
Who will be the leaders in applying this knowledge for the most effective and most cost-ffective approaches? I suggest that it is the interventional cardiologists who should lead. There
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900hould not be a conflict with primary care physicians or
ur noninvasive colleagues, but “atherothrombosis is our
ife” and we should not abandon the chronic care or early
etection of this condition.
If the cath lab and imaging businesses suffer, the
aiting room may flourish. The patients we stent need
ur expert medical care. Their families with similar
enetic make-up and lifestyle habits need to be identified
nd their disease interrupted if it is present, and when
ndividuals are identified at low risk, then expert advice to
void unnecessary medical expense should be given.
The future of interventional cardiology will take many
orms. Some operators will apply highly-specialized tech-
iques for treating structural defects. We may see a day
hen regenerative medicine will necessitate interventional
ethods for rebuilding failing hearts. But in the near term,
e are the experts in atherothrombosis. If we want to align
ur profession with our business, why not take advantage of
he tide of opinion? There should be increased emphasis on
revention and medical therapy applied by those with the
bility to intervene, if required, but focused on avoiding the
eed for further interventions.
Talk radio commentators decry health care reform withny government involvement as communism in disguise. shysicians are bombarded with propaganda from the in-
urance industry and others that a public option for insur-
nce is going to reduce their income. As I remember,
he 1965 fight against Medicare the arguments were
imilar, but if Medicare legislation had not passed, we
ould all be living in smaller houses. Universal cover-
ge and affordable drug pricing are not radical ideas.
opefully some meaningful legislation will be enacted
hat will improve the fight against our main nemesis,
therothrombosis. However, whatever system evolves,
ur profession demands that care for our patients
hould be our central concern. Available evidence
oints to our interventional procedures as important
olutions for many conditions. The evidence also sug-
ests that whatever system evolves we should apply our
pen” as well as our stents.
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